FDA Clears First Blood-Based Biomarker Test for Alzheimer's: What It Means for Patients and Providers Diagnosing Alzheimer’s disease could be as simple as a routine blood draw thanks to the FDA’s recent clearance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio. This innova... Alzheimer's biomarkers diagnostics FDA clearance Fujirebio neurodegenerative diseases plasma test
How Stromal Disruption Could Transform Breast Cancer Risk Detection Imagine if a simple tissue test could alert doctors to women at greater risk for aggressive breast cancer, long before symptoms appear. That’s the promise behind new research from NIH scientists, who ... biomarkers breast cancer cancer risk machine learning NIH research prevention stromal disruption women’s health